Sample Page

DODB, also known as 2,5-dimethoxy-4,6-dibromoamphetamine or as 6-bromo-DOB, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families related to DOB.[1] It is the 6-bromo derivative of DOB and the 4,6-dibromo derivative of 2,5-dimethoxyamphetamine (2,5-DMA; DOH).[1] The drug has a dose range of 5 to 8 mg orally and a duration of 12 to 20 hours.[1] For comparison, DOB has a dose of 1 to 3 mg and a duration of 18 to 30 hours.[1] DODB is described as having largely the same effects as DOB.[1] However, it is said that the drug may have somewhat greater visual effects than DOB and that its physical side effects appear to be less pronounced than those of DOB.[1] DODB was synthesized and tested by P. Rausch in the 1990s or 2000s.[1][2] It was described in the scientific literature by Daniel Trachsel in 2013, who cited personal communication with Rausch as the source for the information.[1] The drug is a controlled substance in Canada under phenethylamine blanket-ban language.[3]

See also

References

  1. ^ a b c d e f g h i j Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. p. 921. ISBN 978-3-03788-700-4. OCLC 858805226. Archived from the original on 21 August 2025.
  2. ^ Rausch P (January 1995). Leuner H, Schlichting M (eds.). Jahrbuch des Europäischen Collegiums für Bewußtseinsstudien: 1995 [Yearbook of the European College for the Study of Consciousness: 1995] (in German and English). Vol. 4. Berlin: VWB. ISBN 3861354071. ISSN 0942-7600. OCLC 28636362.
  3. ^ “Controlled Drugs and Substances Act”. Department of Justice Canada. Retrieved 19 January 2026.